Dr. Lal Path Labs cash flow

Latest FY26

Cash from operations: ₹636cr+11.8% on FY25
Capital spending: ₹173cr+221.7% on FY25
Free cash flow: ₹462cr−10.2% on FY25
Cash from financing: −₹264cr−₹334 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	162	142	144	150
	—	0.0	3.4	0.0	7.6
	—	22.8	22.3	29.4	37.5
	—	−67.0	−66.5	−55.4	−33.2
	—	−19.4	0.0	−10.4	0.8
	—	23.8	27.2	21.7	22.8
	—	0.2	0.0	−0.2	−0.4
	—	0.0	0.0	−0.5	−2.4
	—	−11.7	0.0	0.0	0.0
	—	4.9	−26.3	−2.0	0.0
	—	−7.7	1.2	−3.5	18.7
	—	−26.8	−15.3	−7.3	3.3
	—	−0.8	−0.9	1.8	1.1
	—	−2.7	0.0	0.0	0.0
	—	0.6	−2.6	−3.9	2.2
	—	13.5	12.3	30.5	9.2
	—	5.5	4.0	6.1	2.1
	—	−1.0	8.1	3.3	−3.0
	—	46.0	−0.8	8.7	2.1
Cash from operating activities
	717	669	625	506	344
	—	142	108	162	219
	—	811	733	667	563
	—	175	164	132	107
	—	636	569	535	456
Cash from investing activities
	—	167	44.3	51.2	36.5
	—	6.4	9.6	6.3	8.1
	—	0.5	0.7	0.9	0.5
	—	0.0	0.0	0.0	17.8
	—	0.0	0.0	0.4	0.0
	—	66.4	63.1	45.3	30.6
	—	−315	−313	−12.6	−256
	—	−422	−303	−24.3	−287
Cash from financing activities
	—	18.6	12.7	0.0	0.9
	—	0.0	0.0	3.5	0.0
	—	0.0	83.3	153	109
	—	36.8	33.8	33.5	34.2
	—	22.8	22.3	29.4	37.8
	—	223	207	201	103
	—	0.0	0.0	0.0	−0.1
	—	−264	−334	−414	−283
	—	−49.8	−68.3	97.2	−115
	—	−49.8	−68.3	97.2	−115
	—	243	293	361	264
Reference items
	838	783	696	609	490
	29.0%	28.3%	28.3%	27.4%	24.3%
	462	462	515	478	411
	—	440	409	295	—
	₹27.58	₹27.58	₹30.72	₹28.51	₹24.55
	69.31×	—	—	—	—
	—	1.25×	1.16×	1.48×	1.89×
	—	175	164	132	107
	—	22.8	22.3	29.4	37.8

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

LALPATHLAB₹1,911.70

Dr. Lal Path Labs Ltd.

· Pharma & Health

₹ CrorePeersMETROPOLIS VIJAYA THYROCARE NATCOPHARM NEULANDLAB NH COHANCE SAILIFEMcap ₹32,040 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	150.2	143.6	141.9	161.8	—
+ Impairment Loss / (Reversal)	7.6	0.0	3.4	0.0	—
+ Finance Costs	37.5	29.4	22.3	22.8	—
+ Interest Income	-33.2	-55.4	-66.5	-67.0	—
+ Fair Value (Gains) / Losses	0.8	-10.4	0.0	-19.4	—
+ Share-based Payments	22.8	21.7	27.2	23.8	—
+ Unrealised FX (Gain) / Loss	-0.4	-0.2	0.0	0.2	—
+ Other Non-cash Items	-2.4	-0.5	0.0	0.0	—
+ Other — Cash Effects are Investing / Financing	0.0	0.0	0.0	-11.7	—
+ Other Reconciling Items	0.0	-2.0	-26.3	4.9	—
Changes in Working Capital
+ Inventories	18.7	-3.5	1.2	-7.7	—
+ Trade Receivables — Current	3.3	-7.3	-15.3	-26.8	—
+ Other Financial Assets — Current	1.1	1.8	-0.9	-0.8	—
+ Other Financial Assets — Non-current	0.0	0.0	0.0	-2.7	—
+ Other Current Assets	2.2	-3.9	-2.6	0.6	—
+ Trade Payables — Current	9.2	30.5	12.3	13.5	—
+ Other Financial Liabilities — Current	2.1	6.1	4.0	5.5	—
+ Other Current Liabilities	-3.0	3.3	8.1	-1.0	—
+ Provisions — Current	2.1	8.7	-0.8	46.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	343.9	505.5	624.7	669.1	716.7
+ Total Adjustments (incl. Working Capital)	218.6	161.9	108.0	142.0	—
Cash from Operations (pre-tax)	562.5	667.4	732.7	811.1	—
+ Income Taxes Paid	106.5	132.0	163.9	175.4	—
Cash from Operating Activities	456.0	535.4	568.8	635.7	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	36.5	51.2	44.3	167.0	—
+ Acq of Intangible Assets	8.1	6.3	9.6	6.4	—
+ Disp of Fixed Assets	0.5	0.9	0.7	0.5	—
+ Purchase of Investments (Equity / Debt)	17.8	0.0	0.0	0.0	—
+ Acq of Subsidiaries / Businesses (net)	0.0	0.4	0.0	0.0	—
+ Interest Received — Investing	30.6	45.3	63.1	66.4	—
+ Other Inflows / (Outflows) — Investing	-256.0	-12.6	-313.0	-315.4	—
Cash from Investing Activities	-287.3	-24.3	-303.1	-421.9	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.9	0.0	12.7	18.6	—
+ Proceeds from Exercise of Stock Options	0.0	3.5	0.0	0.0	—
+ Repayment of Borrowings	109.0	153.3	83.3	0.0	—
+ Payment of Lease Liabilities	34.2	33.5	33.8	36.8	—
+ Interest Paid	37.8	29.4	22.3	22.8	—
+ Dividends Paid	103.0	201.2	207.3	222.6	—
+ Other Inflows / (Outflows) — Financing	-0.1	0.0	0.0	0.0	—
Cash from Financing Activities	-283.2	-413.9	-334.0	-263.6	—
Net Changes in Cash (pre-FX)	-114.5	97.2	-68.3	-49.8	—
Net Changes in Cash	-114.5	97.2	-68.3	-49.8	—
Closing Cash	263.7	360.9	292.6	242.8	—
Reference Items
EBITDA	489.9	609.3	695.5	782.5	837.7
EBITDA Margin %	24.29	27.36	28.26	28.32	28.98
Free Cash Flow (CFO − Capex)	411.4	477.9	514.9	462.3	462.3
Free Cash Flow to Equity	—	295.2	409.3	439.5	—
Free Cash Flow per Basic Share	24.55	28.51	30.72	27.58	27.58
Price to Free Cash Flow	—	—	—	—	69.31
Cash Flow to Net Income	1.89	1.48	1.16	1.25	—
Cash Paid for Taxes	106.5	132.0	163.9	175.4	—
Cash Paid for Interest	37.8	29.4	22.3	22.8	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.